Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
O.G. Kostyuk, B.A Bolyuh, G.Y. Kostyuk, V.G. Kostyuk, O.O. Konovalyuk Condition of animals with superficial bladder cancer after submucosal administration of chemotherapy. The problem of superficial bladder cancer fails to excite scientists around the world. The complexity of the etiology and pathogenesis, a large variability in clinical presentation, a variety of morphological forms, the presence of severe complications that often lead to disability and often lethal outcomes, these all allow us to consider the issue relevant to our time and unsolved. On the surface localization of the tumor in the mucosa and submucosa of urinary bladder indicates the bulk of the literature. Thus, some authors state that approximately 75-80% of all patients with the initially diagnosed cancer of the urinary bladder the tumor locates superficially (Tis, Ta, T1), in other cases it is determined by the germination of the tumors in the muscle membrane of the urinary bladder and lymph glands. The experiments were conducted on the 15 outbred, opposite-sex, mature dogs. At the creating the models of cancer all animals didn’t have any significant changes in behavior, receiving food, without changes in blood parameters, satisfactorily carried 6-10-month feeding with β-naftilaminom. All animals, after its use on the surface layer of the bladder have single or multiple tumors. The 12 animals (80%) have the presence of multicentric growth of cancerous tumors. The research of urine was conducted for some occult blood (azopiromov test) and the research of urine cytology all of these were done to use the submucosal administration of doxorubicin and mitomycin-C, with the purpose to form drug depots in the submucosa, in the case of the surgical intervention. The results of these studies were used to determine the initial changes in the epithelium of the urinary bladder and to prevent tumor invasion into the muscle membrane. The received data showed that during the usage of β-food naftilaminu the initial number of leukocytes, and the number of leukocytes before the operative intervation, were not significantly changed for the whole period of the feeding. That is, a significant impact on the overall condition of the animals in the case of the usage of this drug is not observed. Typical that there was a slight leukocytosis in the early days of the postoperative period. The number of leukocytes remained elevated compared with initial values, and even on the third day. Two weeks later, leukocyte count gradually decreased and approached to the normal state. The gradual reduction of their number after submucosal administration of chemotherapy was observed up till eight weeks of the study, with the following normalization of peripheral blood leukocytes. In ten weeks, it corresponded to the initial value. The observations of much longer period (in one and two years) showed that the number of leukocytes in peripheral blood swung in the range of the norm. The indicator of red blood cells changed in different way. At the early stages of observation, from the beginning of feeding with β-naftilaminu to the operative intervation on urinary bladder, the number in this group of animals was close to normal. After submucosal administration of chemotherapy in the first 3 days the red blood cells were significantly elevated to the initial values. In more remote period their number gradually decreased. To two animals after ingestion of β-naftilaminu in submucosa the chemotherapy is not administered. They served as a comparative group, who were not carried out the treatment anticancer drugs. These animals in 3-4 months after discontinuing use of β-naftilaminu with food were observed the changes in behavior in the form of reduced activity (most of the time the dogs were lying, they had a weak reaction on the nickname and sound stimulus, decreased the amount of food which they ate) . The both animals were paid attention with a significant decrease of the body weight. One animal died in 6 months, the second animal died in 10 months after discontinuing the use of β-naftilaminu. No specific treatment affected adversely the condition of animals. Conclusions. 1. The use of β-naftilamin leads to the development of tumors of urinary bladder is created superficial bladder cancer model that allows us to track the process of recovery of the animals in the application of a method of treatment of superficial bladder cancer. 2. Lack of specific antitumor treatment leads to the fatal consequences. 3. The animals after submucosal administration of chemotherapy in the later periods of leukocytes and erythrocytes in the peripheral blood ranged norm. 4. The behavior of animals and their feed consumption in submucosal administration 0,0125% chemical solution in terms of distance, does not differ from those in intact dogs.